Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Monte Rosa Therapeutics (GLUE) Cash & Equivalents (2023 - 2025)

Monte Rosa Therapeutics (GLUE) has 3 years of Cash & Equivalents data on record, last reported at $401.6 million in Q3 2025.

  • For Q3 2025, Cash & Equivalents rose 219.83% year-over-year to $401.6 million; the TTM value through Sep 2025 reached $401.6 million, up 219.83%, while the annual FY2024 figure was $224.3 million, 75.06% up from the prior year.
  • Cash & Equivalents reached $401.6 million in Q3 2025 per GLUE's latest filing, up from $69.4 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $401.6 million in Q3 2025 and bottomed at $47.0 million in Q2 2023.
  • Average Cash & Equivalents over 3 years is $126.7 million, with a median of $99.8 million recorded in 2024.
  • The widest YoY moves for Cash & Equivalents: up 219.83% in 2025, down 36.21% in 2025.
  • A 3-year view of Cash & Equivalents shows it stood at $128.1 million in 2023, then soared by 75.06% to $224.3 million in 2024, then soared by 79.09% to $401.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cash & Equivalents were $401.6 million in Q3 2025, $69.4 million in Q2 2025, and $78.5 million in Q1 2025.